The Effect of Prucalopride on Gastric Emptying in Intensive Care Unit Patients

• Status: Completed
• Trial end date: 2022-07-15
• Target enrollment: 0
• Participant gender: All

Summary

to compare the effectiveness as well as the safety of prucalopride against metoclopramide as the first line treatment for feeding intolerance in critically ill patients.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Collaborator: Future University in Egypt
• Treatments: Metoclopramide; Prucalopride

Criteria

Inclusion Criteria:

• Patients aging between 18 and 60 years (of both sexes) who are admitted to the ICU and are expected to stay in the ICU for not less than 7 days and are prescribed enteral feeding through naso- or oro-gastric tube whose modified nutritional risk in the critically ill (mNUTRIC) score is of more than or equal

Exclusion Criteria:

• Patients who met the following criteria were excluded:

• Age less than 18 years or more than 60 years.

• Previous upper gastrointestinal tract surgery, obstruction, hemorrhage or history of GI disease.

• Clinically significant hepatic dysfunction. (>3 times above the upper end of normal range of bilirubin, γ-glutamyl transferase, aspartate transaminase, or lactate dehydrogenase)

• Regular use of H2 blockers, prokinetic, proton pump inhibitor or anticholinergic agents for previous 4 weeks.

• Patients with arrhythmia or atrioventricular blocks.

• Any condition or comorbid disease that might interfere with gastric emptying such as diabetes.

• Patients with head injuries.